Learn About Gastroesophageal Junction Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Hematology
Oncology
Lifespan
University Medicine
Howard Safran is a Hematologist Oncology specialist and a Hematologist in Providence, Rhode Island. Safran has been practicing medicine for over 36 years and is rated as an Elite expert by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 28 other conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Gastroesophageal Junction Cancer, Colorectal Cancer, and Stomach Cancer. Safran is currently accepting new patients.
Hematology
Oncology
Memorial Sloan Kettering Cancer Center
Yelena Janjigian is a Hematologist Oncology specialist and a Hematologist in New York, New York. Janjigian has been practicing medicine for over 20 years and is rated as an Elite expert by MediFind in the treatment of Gastroesophageal Junction Cancer. She is also highly rated in 6 other conditions, according to our data. Her top areas of expertise are Gastroesophageal Junction Cancer, Stomach Cancer, Esophageal Cancer, Liver Embolization, and Endoscopy. Janjigian is currently accepting new patients.
National Cancer Center Hospital East
Kohei Shitara practices in Kashiwa, Japan. Shitara is rated as an Elite expert by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 9 other conditions, according to our data. His top areas of expertise are Stomach Cancer, Gastroesophageal Junction Cancer, Colorectal Cancer, Gastrectomy, and Endoscopy.
Summary: This phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other places in the body (metastatic), has come back (recurrent), or cannot be removed by surgery (unresectable). Olaparib may stop the growth of tumor cells by blocking some of ...
Summary: Oxaliplatin in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.